Claims:

1. The use of a LINK_TSG6 polypeptide in the manufacture of a medicament for the treatment or prevention of an ocular surface disorder such as dry eye disease.

2. The use according to claim 1, wherein the treatment or prevention of an ocular surface disorder such as dry eye disease comprises one or more effects selected from the group consisting:
   healing of corneal epithelial defects;
   increase in tear production;
   suppression of inflammation; and
   a higher number of conjunctival goblet cells.

3. The use according to claim 1 or claim 2 wherein the treatment comprises topical administration of LINK_TSG6 polypeptide to the eye.

4. The use according to any one of claims 1 to 3 wherein the treatment comprises administering LINK_TSG6 polypeptide two times per day.

5. The use according to any one of claims 1 to 3 wherein the treatment comprises administering LINK_TSG6 polypeptide less than four times per day.

6. The use according to claim 3 wherein the LINK_TSG6 polypeptide is formulated as an eye drop.

7. The use according to any one of the preceding claims wherein LINK_TSG6 is co-administered with one or more of prednisolone, cyclosporine, Lifitegrast (Xiidra™) or artificial tears.

8. The use according to any one of the preceding claims wherein about 10µg-200µg LINK_TSG6 polypeptide is administered per eye, preferably 120µg-150µg LINK_TSG6 polypeptide is administered per eye.

9. The use according to claim 2, wherein the suppression of inflammation comprise a decrease in the production of one or more pro-inflammatory cytokines in the cornea or the intraorbital lacrimal glands, the pro-inflammatory cytokines optionally selected from TNF-α, IL-6, IFN-γ and IL-1β.

10. The use according to claim 2 wherein the treatment or prevention of dry eye disease comprises healing of corneal epithelial defects, increase in tear production, suppression of inflammation or increase in number of conjunctival goblet cells as compared to the corneal epithelial defects, tear production, inflammation or number of conjunctival goblet cells prior to the administration of LINK_TSG6 polypeptide.

11. The use according to claim 2 wherein the treatment or prevention of dry eye disease comprises healing of corneal epithelial defects, increase in tear production, suppression of inflammation or

increase in number of conjunctival goblet cells as compared to the corneal epithelial defects, tear production, inflammation or number of conjunctival goblet cells as compared to a control individual treated with full-length TSG-6 protein.

12. The use according to any one of the preceding claims wherein the individual being treated has Sjögren's syndrome.

13. The use according to any one of the preceding claims wherein the treatment comprises the administration of an eye drop comprising LINK_TSG6.

14. The use according to any one of the preceding claims, wherein the LINK_TSG6 polypeptide comprises, consist, or consists essentially of (i) the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 9, or (ii) an amino acid sequence having at least 80% identity to the amino acid sequence of SEQ ID NO: 7 or 9.

15. An eye drop formulation comprising LINK_TSG6 polypeptide.

16. The eye drop formulation according to claim 15 comprising between 240µg/ml and 3000µg/ml, preferably between 2400µg/ml and 3000µg/ml.

17. The eye drop formulation according to claim 15 or claim 16 further comprising prednisolone, cyclosporine, Lifitegrast (Xiidra™) or artificial tears.